TEM vs ABBV
diagnostics · AbbVie
| TEM diagnostics Healthcare | ABBV AbbVie Healthcare | |
|---|---|---|
| Market | ||
| Price | $80.92 +3.11% | $289.91 +0.37% |
| Market cap | $13.2B | $521.1B |
| P/E (TTM) | — | 82.6 |
| Dividend yield | — | 4.47% |
| 52-week range | $40.77 – $91.83 | $190.75 – $298.74 |
| Our research | ||
| Our view | LONG open | LONG open |
| Articles | 1 | 1 |
| Latest article | Tempus Grew Revenue 23%, But A $42.8 Million Securities Gain Helped The Loss Nov 3, 2026 | AbbVie Q3 2026: Skyrizi And Rinvoq Are 49% Of Revenue, And Adjusted EPS Includes IPR&D Nov 2, 2026 |
| Latest earnings | ||
| Reported | — | Oct 30, 2026 |
| Revenue | — | $17.404 billion +10.3% YoY |
| EPS | — | $2.37 |
| Guidance | — | Guidance raised |
| Revenue growth, last 4 reports | — | +10.3% |
| Topics | ||
| Main topics | ||
| Company page | Company page · Earnings releases | |
Note. Earnings figures are extracted automatically from each company's own release; prices are delayed up to 15 minutes. This comparison is information, not investment advice.